Il-20 activates erk1/2 and suppresses splicing of x-box protein-1 in intestinal epithelial cells but does not improve pathology in acute or chronic models of colitis

HIGHLIGHTS

• who: Md. Moniruzzaman and collaborators from the Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia have published the research work: IL-20 Activates ERK1/2 and Suppresses Splicing of X-Box Protein-1 in Intestinal Epithelial Cells but Does Not Improve Pathology in Acute or Chronic Models of Colitis, in the Journal: (JOURNAL)
• what: By using chemical-induced (dextran sodium sulphate; DSS) colitis and a spontaneous model of colitis (Winnie mice) the authors assess whether recombinant IL-20 treatment is beneficial in reducing/improving pathology. This study has been undertaken to understand the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.